Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MiMedx GroupMDXG +1.55%57 EV-to-EBIT is 12.09 as of Jul. 27, 2026, which is 16% above its 10-year median of 10.45. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.70 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 378 Biotechnology companies, MiMedx Group ranks better than 52.12% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
MiMedx Group's Enterprise Value for the quarter that ended in Mar. 2026 was $446.1 Mil.
MiMedx Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group EV-to-EBIT Related Terms
MiMedx Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for MiMedx Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where MiMedx Group's EV-to-EBIT falls into.
MiMedx Group's current Enterprise Value is $492.3 Mil.
MiMedx Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a EV-to-EBIT of 12.09 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MiMedx Group and its competitors. This is 16% above median its historical median of 10.45. According to the industry distribution chart, MiMedx Group ranks #181 out of 378 companies in the Biotechnology industry, placing it in the top 47.9%.
Is MiMedx Group's EV-to-EBIT too high?
MiMedx Group's current EV-to-EBIT of 12.09 is 16% above median its 10-year median of 10.45. The Biotechnology industry median EV-to-EBIT is 12.78. MiMedx Group's value of 12.09 is 5.4% below this industry median. Based on the distribution chart, MiMedx Group ranks #181 out of 378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's EV-to-EBIT compare to RGNX and ACHV?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #181 out of 378 companies for EV-to-EBIT. This puts MiMedx Group in the upper half of its industry. The industry median EV-to-EBIT is 12.78. MiMedx Group's value of 12.09 is 5.4% below this benchmark. While the company's 10-year median is 10.45 vs. the industry median of 12.78, MiMedx Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.78, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current EV-to-EBIT of 12.09 is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current EV-to-EBIT is 12.09, which is 16% above median its own 10-year median of 10.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.70, compared to a current price of $4.26 — trading 36.4% below its estimated fair value. The current EV-to-EBIT is 12.09, which is 16% above median its 10-year median of 10.45 and 5.4% below the Biotechnology industry median of 12.78. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For MiMedx Group (MDXG), the current EV-to-EBIT is 12.09 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $4.26 is trading 36.4% below its estimated GF Value™ of $6.70.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
EV-to-EBIT: 12.09 (16% above median its 10-year median of 10.45)
GF Value™: $6.70 vs. price of $4.26 (36.4% below fair value)
Industry Position: 5.4% below the Biotechnology median (#181 of 378)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
